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Circular RNAs (circRNAs) comprise an emerging new class of endogenous
RNAs expressed abundantly by the eukaryotic transcriptome. They are
characterized by a covalently closed loop structure, resulting in RNA mole-
cules that are more stable than linear RNAs. A growing number of studies
indicate that circRNAs play critical roles in human diseases and show great
potential as biomarkers and therapeutic targets. The molecular events
determined by circRNA activity, the circRNA code, involve other types of
noncoding RNA molecules, primarily microRNAs, long noncoding RNAs,
and RNA-binding proteins. Herein, we mainly focus on the circRNA–mi-
croRNA code, showing how this relationship impacts the regulation of
gene expression in cancer. The emerging roles for circRNAs in oncogenic
pathways highlight new perspectives for the detailed molecular dissection
of cancer pathogenesis and, at the same time, offer new opportunities to
design innovative therapeutic strategies. Here, we review recent research
advancements in understanding the biogenesis, molecular functions, and
significance of circRNAs in cancer diagnosis and treatment.
1. Introduction
Circular RNAs (circRNAs) are an abundant class of
endogenous RNAs, which have recently been rediscov-
ered and re-evaluated for their important roles in the
regulation of gene expression (Jeck and Sharpless,
2014). These covalently closed circular RNA molecules
were previously considered as viroids (Sanger et al.,
1976), Hepatitis delta virus molecules (Kos et al., 1986)
and splicing error result (Cocquerelle et al., 1993).
Many progresses on circRNAs characterization have
been made recently. However, full comprehension of
their biogenesis and function remains elusive. cir-
cRNAs partly originate from protein-coding genes and
can be represented by one exon or by a combination of
several exons. circRNAs are characterized by the lack
of 30 poly(A) tails and 50 end caps. Due to the absence
of accessible ends, circRNAs are resistant to exonucle-
ase RNase R and more stable than the corresponding
linear RNA isoforms (Jeck and Sharpless, 2014;
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Memczak et al., 2013). Nevertheless, circRNAs are
usually expressed at lower levels than their host genes,
although it is not the rule (Enuka et al., 2016; Salzman
et al., 2012, 2013). Indeed, Liang et al. (2017) showed
that the levels of Drosophila circRNAs strongly
increase upon inhibition or slowing of multiple canoni-
cal pre-mRNA processing events. This condition is pro-
moted by the long half-lives of circular RNAs.
Recently, circRNAs emerged for their association
with human diseases and in particular with cancer,
suggesting their possible use as new biomarkers and
therapeutic targets (Chapman et al., 2012; Chen et al.,
2017; Li et al., 2015b,c; Memczak et al., 2015).
2. Biogenesis of circRNAs
circRNAs can be distinguished based on their origin.
Although the exonic circRNAs (ecircRNAs) represent
the most abundant part, circRNAs can also derive from
intronic, antisense, 50- or 30-untranslated, and intergenic
genomic regions (Salzman et al., 2012). circRNAs com-
prised of exonic sequences are produced by a mecha-
nism called ‘back-splicing’ where a downstream 50 splice
site of an exon is joined to an upstream 30 splice site of
another exon, involving single or multiple exons (Ash-
wal-Fluss et al., 2014; Ivanov et al., 2015; Jeck and
Sharpless, 2014; Liang and Wilusz, 2014; Starke et al.,
2015; Zhang et al., 2014) (Fig. 1). The result of this
mechanism is a covalently closed circular transcript and
an alternatively spliced linear RNA with skipped exons.
Most circRNAs are hosted by protein-coding genes,
indicating that RNA polymerase II (RNA pol II) is
responsible for their transcription and that their bio-
genesis is mediated by spliceosomes. Indeed, Ashwal-
Fluss et al. (2014) showed that the circRNAs are gen-
erated cotranscriptionally competing with canonical
pre-mRNA splicing and consequently affecting the rate
of canonical gene expression (Ashwal-Fluss et al.,
2014). Later, Starke et al. (2015) showed that the exon
back-splicing mechanism requires the canonical spliceo-
somal machinery.
There are two current models explaining the forma-
tion of circRNAs: the exon skipping or lariat interme-
diate model, and the direct back-splicing model (Chen
and Yang, 2015) (Fig. 1). In the exon skipping or lar-
iat intermediate model, canonical splicing occurs first,
generating a linear RNA with skipped exons. The long
intron lariat containing these skipped exons is gener-
ated determining the production of circRNA by back-
splicing. In the direct back-splicing model, processing
starts with back-splicing determining a circRNA and
an exon–intron(s)–exon intermediate, which can be
processed in a linear RNA with skipped exons (Chen
and Yang, 2015; Jeck et al., 2013; Memczak et al.,
2013) (Fig. 1).
The mechanism of circular RNA biogenesis is asso-
ciated with Alu elements (Arthrobacter luteus ele-
ments), identified upstream and downstream of the
flanking introns of circularized exons (Jeck et al.,
2013). Moreover, it has been shown that Alu elements
can compete between them generating multiple cir-
cRNAs from a single gene locus (Jeck et al., 2013;
Salzman et al., 2013; Zhang et al., 2014).
The biogenesis of circRNAs is also regulated by
splicing factors and RNA-binding proteins (Ashwal-
Fluss et al., 2014; Conn et al., 2015). The splicing fac-
tor muscleblind (MBL) can promote circRNA biogen-
esis. MBL promotes the circularization of the circular
RNA circMBL, binding to the introns flanking the
circRNA generated from the second exon of its own
RNA (Ashwal-Fluss et al., 2014). Interestingly, the
circRNA also contains binding sites for its parental
gene MBL (Ashwal-Fluss et al., 2014). This is an exam-
ple of how a splicing factor can regulate the production
of circRNAs. The MBL example also provides evi-
dence that circRNAs are generated cotranscriptionally,
competing with the canonical splicing of pre-mRNA.
In analogy, the RNA-binding protein quaking-5
(QKI-5) promotes circRNA biogenesis during epithe-
lial-to-mesenchymal transition (EMT) binding the
introns flanking the circRNA-forming exons (Conn
et al., 2015). QKI-5, the most abundant isoform, has
been found to act as a tumor suppressor in cancer
(Zhao et al., 2014). For example, in prostate cancer,
QKI-5 is downregulated as a consequence of hyperme-
thylation of the respective promoter. In addition,
QKI-5 inhibits cell proliferation and promotes cancer
cell apoptosis (Zhao et al., 2014). QKI-5 has been
found to be downregulated also in lung cancer, and
this associates with poorer patient’s prognosis. Inter-
estingly, the tumor suppressor action of QKI-5 relates
to an ability to regulate alternative splicing of NUMB,
a key target of the Notch signaling pathway (Zong
et al., 2014). Under nontumoral conditions, the exclu-
sion of exon 12 of NUMB’s pre-mRNA determines
the block of Notch. In a context where QKI-5 is
downregulated, as it is in cancer, NUMB is expressed
with the inclusion of the exon 12, resulting in an iso-
form able to activate Notch (Zong et al., 2014).
The tumor suppressor role of QKI-5, combined with
its capability to promote circRNA biogenesis during
EMT, suggests a central role for QKI-5 in the regula-
tion of circRNAs biogenesis in cancer. Indeed, EMT
plays an important role in promoting cancer metastasis
(Conn et al., 2015; Tsai and Yang, 2013; Zhao et al.,
2014; Zong et al., 2014).
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Further investigations will be necessary to com-
pletely elucidate the mechanism and regulation of cir-
cRNA biogenesis.
3. Known mechanisms of action of
circRNAs
Different computational pipelines have been developed
in order to identify and quantify circRNAs based on
data of the high-throughput RNA sequencing technol-
ogy (RNA-seq) (Enuka et al., 2016; Guo et al., 2014;
Jeck et al., 2013; Salzman et al., 2012). Although all
approaches employed demonstrated generation of cir-
cRNAs from several human loci, their mechanism of
action and biological importance remain controversial.
Guo et al. (2014) identified thousands of circRNAs
from a large variety of human cell lines. They argued
that, with a few exceptions, circRNA did not show the
properties of microRNA (miRNA) sponge and they
could be only alternative isoform of their respective
primary transcript (Guo et al., 2014). Congruent with
this line of evidence, while stimulation of mammary
cells with the epidermal growth factor (EGF) leads to
dynamic changes in the abundance of many coding
and noncoding RNA molecules and culminates in the
acquisition of a robust migratory phenotype, cir-
cRNAs of EGF-stimulated mammary cells are stably
expressed, while mRNAs and miRNAs change within
minutes (Enuka et al., 2016). The capability to act as
miRNA sponge was one of the first mechanisms of
action attributed to circRNAs (Hansen et al., 2013).
Recently, the evidences for circRNAs acting as
miRNA sponge are growing and it seems to be one of
the most favorite mechanisms in cancer. Several
groups working independently showed that circRNAs
exert important roles in gene expression regulation by
different mechanisms. These RNA molecules can regu-
late alternative splicing (Ashwal-Fluss et al., 2014;
Zhang et al., 2014) and sequester RNA-binding pro-
teins and ribonucleoprotein complexes (Hansen et al.,
2013; Salzman et al., 2012). In addition, circRNAs can
be translated and bind in trans to other RNA
Fig. 1. Models proposed to explain the biogenesis of circRNAs. A schematic representation of the two models that generate circRNAs: left,
the exon skipping or lariat intermediate model; right, the direct back-splicing model.
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sequences (Jeck and Sharpless, 2014). A list of cir-
cRNAs involved in cancer and discussed here is shown
in Table 1.
3.1. circRNAs can act as miRNA sponges
Acting as competing endogenous RNA (ceRNA), or
miRNA sponge, circRNAs can bind miRNAs through
a miRNA response element (MRE) and negatively reg-
ulate their activity (Memczak et al., 2013). Since the
length of exon circRNAs goes from 100 nt to more
than 4 kb (Lasda and Parker, 2014), the potential
number of MREs is variable and relates to the length
of the circRNAs, as well as to its nucleotide sequence
(Fig. 2).
The miRNAs are an abundant class of small non-
coding RNAs approximately 22 nucleotides long. They
act as negative regulators of gene expression at the
post-transcriptional level, by means of binding their
target mRNAs through imperfect base pairing with the
respective 30-untranslated region (30-UTR) (Lewis
et al., 2005) (Fig. 2).
As miRNA sponges, circular RNAs can function as
oncogenes or as tumor suppressor genes. We describe
below some significant examples of circRNAs acting
as miRNA sponges in a wide range of cancers.
One of the first identified human circRNAs acting
like miRNA sponges was the antisense to the cerebel-
lar degeneration-related protein 1 transcript (CDR1as),
also known as ciRS-7. CDR1as is able to bind miR-7
using more than 70 conserved miRNA target sites, a
miRNA sponge first identified in zebrafish neuronal
tissues. CDR1as’ expression in zebrafish impairs mid-
brain development, a phenotype similar to morpholino
miR-7 knockdown. Later, CDR1as was found to be
upregulated in hepatocellular carcinoma, where its
expression level was inversely correlated with that of
miR-7 (Yu et al., 2016). miR-7 plays an important role
in the biology of many cancers, including hepatocellu-
lar carcinoma (Fang et al., 2012), tongue carcinoma
(Jiang et al., 2010), schwannoma (Saydam et al.,
2011), gastric carcinoma (Kong et al., 2012), and cervi-
cal cancer (Liu et al., 2013). It follows that the action
of CDR1as can have significant implications in many
types of cancers.
The circular transcript of the testis-determining gene
(Sry) was discovered many years ago, but only recently
its role as a miRNA sponge has been clarified (Capel
et al., 1993). Sry sponges miR-138 due to its 16 target
sites for this miRNA (Hansen et al., 2013). Sry seems
to act in cancer like an oncogene targeting the tumor
suppressor miR-138. miR-138 is significantly downreg-
ulated in anaplastic thyroid carcinoma (ATC), where it
regulates cyclin D3 (CCND3), as well as in hepatocel-
lular carcinoma (HCC), where it regulates the human
telomerase reverse transcriptase (hTERT) (Mitomo
et al., 2008; Wang et al., 2012).
In addition to sponging a single type of miRNA,
some circRNAs may regulate more than one miRNA.
This seems to be the case with the circular RNA circ-
ITCH. circ-ITCH is derived from several exons of the
E3 ubiquitin (Ub) protein ligase (ITCH). Li et al.
(2015a) showed that circ-ITCH is downregulated in
esophageal squamous cell carcinoma (ESCC) and it is
able to influence the expression level of its host gene,
ITCH (Li et al., 2015a). circ-ITCH acts as a miRNA
sponge in ESCC by binding with miR-17, miR-214,
and miR-7 and thereby increases the level of the linear
form ITCH’s mRNA. The latter shares with circ-
ITCH the same miRNAs binding sites, which are
located on its 30-untranslated region (UTR). ITCH is
able to suppress the action of the canonical Wnt path-
way, which plays an important role in carcinogenesis
of many cancer subtypes (Gao and Chen, 2010). Thus,
Table 1. List of circRNAs involved in cancer and discussed in this review.
Name of circRNAs Type of cancer Expression Targets References
CDR1 Hepatocellular carcinoma Up miR-7 Yu et al. (2016)
Sry Anaplastic thyroid carcinoma Up miR-138 Hansen et al. (2013)
circ-ITCH Esophageal squamous cell carcinoma Down miR-17, miR-214, miR-7 Li et al. (2015a)
circHIPK3 Liver cancer Up miR-124 Zheng et al. (2016)
circ-000984 Colorectal cancer Up miR-106b Xu et al. (2017)
circ-TTBK2 Human malignant glioma Up miR-217 Zheng et al. (2017)
circPVT1 Head and neck squamous cell carcinoma Up miR-497-5p Verduci et al. (2017)
Gastric cancer Up miR-125 family Chen et al. (2017)
circ-PABPN1 Cervical carcinoma Down RNA-binding protein HuR Abdelmohsen et al. (2017)
circ-Foxo3 Different cancer cell lines Down p21-CDK2 Du et al. (2016)
circ-Amotl1 Breast cancer Up c-myc Yang et al. (2017)
circ_002059 Gastric cancer Down Unknown Li et al. (2015b)
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circ-ITCH plays an antitumor role in ESCC by indi-
rect inhibition of Wnt signaling.
Zheng et al. (2016) and colleagues generated riboso-
mal-depleted RNA sequences and found many cir-
cRNAs are differently expressed between normal and
cancerous tissues. The authors focused on the circular
RNA circHIPK3, which was significantly upregulated
in liver cancer compared with matched normal tissues.
circHIPK3 derives from HIPK3 mRNA, and differ-
ently from its linear isoform, it acts as a cell growth
modulator in human cells. The oncogenic role of
circHIPK3 is exerted by directly binding to and
inhibiting the tumor suppressor miR-124 (Zheng et al.,
2016).
Xu et al. (2017) showed that the circular RNA hsa_-
circ_000984 is upregulated in colorectal cancer (CRC)
and is able to affect cell proliferation, migration, and
invasion in vitro and tumor formation in vivo. hsa_-
circ_000984 acts as a miRNA sponge that binds with
miR-106b. Interestingly, the authors found that the
host gene of the hsa_circ_000984, the CDK6 gene, is a
target of miR-106b. In its action as a miR-106b
sponge, hsa_circ_000984 shows the capability to regu-
late the CRC carcinogenesis through an indirect
regulation of its host CDK6 gene within a circRNA–
miRNA–mRNA network (Xu et al., 2017).
Zheng et al. (2017) found that circ-TTBK2, but not
linear TTBK2, is upregulated in human malignant
glioma. circ-TTBK2 gains oncogene features by bind-
ing with miR-217, which is usually downregulated in
glioma tissues and cell lines. circ-TTBK2 increases
HNF1b expression in cancer, acting as miR-217
sponge, and as a result, miR-217 cannot negatively
regulate HNF1b by targeting its 30-UTR. HNF1b is
known to activate the transcription of oncogene Der-
lin-1 binding its promoter region (Zheng et al., 2017).
Recently, we showed that the circular RNA
circPVT1 acts as an oncogene in head and neck squa-
mous cell carcinoma (HNSCC). Moreover, the com-
plex containing YAP, TEAD, and a mutant form of
p53 transcriptionally enhances its expression (Verduci
et al., 2017). The phenotype induced by circPVT1
modulation in cancer cell lines appeared to be indepen-
dent from its host gene, PVT1. circPVT1 is able to
bind miR-497-5p by a specific binding site impairing
its tumor suppressor activity. As a result, circPVT1
overexpression in HNSCC determines the upregulation
of the genes aurka, mki67, and bub1, all of which are
Fig. 2. Circular RNAs can affect the miRNA activity. (A) Schematic representation of miRNA mechanism of action. (B) Schematic
representation of circRNAs acting as miRNAs sponge. Three examples of sponge-like circRNAs are shown.
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targets of miRNA-497-5p involved in cell proliferation
(Verduci et al., 2017).
3.2. The circRNA–microRNA code in
tumorigenesis
MicroRNAs (miRNAs) comprise a family of small
noncoding, single-stranded RNAs involved in post-
transcriptional gene silencing (Filipowicz et al., 2008;
Lewis et al., 2005). miRNAs play important roles in a
wide range of biological processes, and they are often
dysregulated in human cancer (Peng and Croce, 2016).
The mechanisms of miRNAs dysregulation are dif-
ferent. They include alterations in genomic miRNA
copy numbers and gene locations leading to amplifica-
tion or deletion of miRNA genes, alterations of the
transcriptional control of miRNAs by transcription
factors that play key role in cancer, dysregulated epi-
genetic changes, such as DNA methylation and histone
acetylation of miRNA genes, and defects in the
miRNA biogenesis machinery (Peng and Croce, 2016).
Compelling evidences showed that the same miR-
NAs might act either as tumor suppressors or as onco-
genes, depending on the cellular context (Peng and
Croce, 2016; Shenouda and Alahari, 2009). Hence, it is
important to consider each miRNA in the context of
specific diseases of interest.
The detection of the tumor in the early phase of its
development is important to increase the chances of
successful treatments. The identification of molecules
that can be used as long-term predictors is crucial not
only for increasing the survival of patients but also for
cancer prevention.
The recent discovery of the circRNA–microRNA
code, in which the two types of RNA molecules inter-
act with one another to determine the regulation of
gene expression, is a promising field of study for early
detection and prognosis of cancer. Our previous stud-
ies described miRNAs that can serve as long-term pre-
dictors of postmenopausal breast cancer risk, that is,
miR-145-3p, miR-145-5p, and miR-513a-5p (Muti
et al., 2014, 2018). To the best of our knowledge, there
are no studies describing the role of circRNAs as long-
term predictors, but this role is likely to be uncovered.
Since circRNAs act as miRNA sponges, it is plausible
that miRNA dysregulation in cancer is due, at least in
part, to the action of circRNAs, in addition to other
known mechanisms.
3.3. circRNAs can interact with proteins
The RNA-binding protein (RBP) HuR can bind sev-
eral circRNAs. In particular, it shows strong
associations with the circular RNA circ-PABPN1 in
human cervical carcinoma HeLa cells (Abdelmohsen
et al., 2017). HuR is responsible for the translation
rate of the PABPN1 gene. High levels of circ-PABPN1
are able to sequester HuR and suppress HuR binding
to the PABPN1 mRNA. Consequently, circ-PABPN1
reduces PABPN1 translation and lowers HeLa cell
proliferation. This is an example of how circRNAs can
affect the translation of their corresponding linear
mRNAs competing with them for a RBP (Abdel-
mohsen et al., 2017).
Du et al. (2016) demonstrated that the circular
RNA circ-Foxo3 is able to inhibit cell proliferation
and cell cycle progression thanks to a ternary complex
with CDK2 and p21. Although circ-Foxo3 acts as a
tumor suppressor, like its host gene Foxo3, the levels
of the circular RNA are not correlated with the level
of the corresponding linear mRNA. The circ-Foxo3-
p21-CDK2 complex repressed CDK2–cyclin A/E com-
plex formation resulting in block of cell cycle progres-
sion (Du et al., 2016).
circ-Amotl1 is highly expressed both in patient
tumor samples and in breast cancer cell lines, where it
acts as an oncogene promoting cancer growth (Yang
et al., 2017). circ-Amotl1 interacts with c-myc increas-
ing the retention of nuclear c-myc, promoting c-myc
stability, and upregulating c-myc targets. Indeed, the
complex circ-Amotl1/c-myc increases the affinity of c-
myc binding to the promoters of the genes HIF-1g,
Cdc25a, ELK-1, and JUN (Yang et al., 2017). Once
again, this proves how the function of circular RNAs
and the function of the respective host genes are ruled
by different mechanisms even if both molecules pro-
mote cancer progression.
3.4. circRNAs as transcriptional regulators
Intronic circRNAs (ciRNAs) and exon–intron cir-
cRNAs (ElciRNAs) represent a peculiar class of cir-
cRNAs. In the study of ciRNAs, a distinction between
ciRNAs and lariat intronic RNA should be made care-
fully.
It has been shown that some ciRNAs and ElciRNAs
can act as transcriptional regulators (Li et al., 2015d;
Zhang et al., 2013). The intron circRNA ci-ankrd52
was found mainly in the nucleus and enriched at its
sites of transcription. ci-ankrd52 is able to regulate its
parent gene expression by modulating RNA poly-
merase II’s elongation activity. The mechanism of
action of this and other intronic circRNAs in the
nucleus suggests a new cis-regulatory role for circular
intronic transcripts in expression of their parental cod-
ing genes (Zhang et al., 2013).
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In similarity to ciRNAs, also the ElciRNAs are
mainly localized to the nucleus. ElciRNAs are RNA
molecules in which the exons are circularized with
introns ‘retained’ in between the exonic sequences.
Similarly to ciRNAs, ElciRNAs can promote expres-
sion of their parental genes by a cis-regulatory mecha-
nism. A specific feature of ElciRNAs, such as
circEIF3J and circPAIP2, is their ability to regulate
their parental genes due to a specific RNA–RNA
interaction between U1 snRNA and ElciRNA (Li
et al., 2015d).
4. circRNAs as products of the RNA-
mediated epigenetic regulation of
gene expression
The field of epigenetics research has been focused for
decades on DNA and histone modifications, giving
marginal attention to RNA modifications, mostly
confined to transfer RNAs (tRNA) and ribosomal
RNAs (rRNA). Recently, the young field of epitran-
scriptomics, considered as any chemical modification
of RNA, is emerging for its important role in cancer
biology, hence attracting a strong research interest.
Considering epitranscriptomics from a wider perspec-
tive, RNA modifications can be classified in two
groups: reversible modifications, such as the different
RNA methylations, and nonreversible modifications,
such as editing and splicing (Esteller and Pandolfi,
2017). According to this classification, circRNAs may
be allocated to the nonreversible modifications of
RNA (Esteller and Pandolfi, 2017). In miRNAs, one
of the most characterized targets of circRNAs up to
now, chemical modifications like adenosines in the
form of m6A, is important for the control of miRNA
expression level (Esteller and Pandolfi, 2017). In par-
ticular, the m6A was found at the junction between
the hairpin stem and the flanking single-stranded
RNA regions of pri-miRNAs (Alarcon et al., 2015b;
Esteller and Pandolfi, 2017). The depletion of this
modification diminished DGCR8 binding to pri-miR-
NAs determining a block in miRNA biogenesis and
failure of mature miRNA production (Alarcon et al.,
2015a).
From an epigenetic point of view, circRNAs by
themselves can be considered an outcome of RNA epi-
genetic regulation. Depending on the role played by
miRNA/miRNAs targeted in cancer, circRNAs can
have a role of tumor suppressor or oncogene. The
study of RNA modification machinery in cancer, in
particular regarding the circRNA–microRNA code, is
an interesting and promising area of research.
5. circRNAs as biomarkers
The unique biochemical features of circRNAs made
this class of RNA molecules promising cancer
biomarkers. Indeed, circRNAs are highly stable and
relatively abundant molecules showing cell-, tissue-,
and developmental-stage-specific patterns of expres-
sion. In addition, circRNAs are highly conserved
among the species and resistant to RNase R activity.
Moreover, circRNAs exist in exosomes and they have
been found in accessible body fluids like saliva,
plasma, and blood (Fig. 3).
Thousands of circRNAs have been detected in
human peripheral whole blood by RNA sequencing
(Memczak et al., 2015). Interestingly, in many cases
circRNA expression levels are higher than the levels of
the corresponding linear RNA isoform (Memczak
et al., 2015).
The circ_002059 has been found significantly down-
regulated in gastric cancer tissues compared with
paired adjacent nontumor tissues (Li et al., 2015b),
showing putatively a tumor suppressor activity. More-
over, the expression level of circ_002059 has been cor-
related with distal metastasis, TNM stage, gender, and
age, showing the importance of this circRNA as a
prognostic marker for gastric carcinoma (Li et al.,
2015b). Another circRNA involved in gastric cancer is
circPVT1. This circular RNA was found to be upregu-
lated in gastric cancer tissues, suggesting an oncogenic
activity (Chen et al., 2017). Indeed, the level of
circPVT1 has been correlated with overall survival and
disease-free survival of patients. circPVT1 acts like an
onco-circular RNA in gastric carcinoma by acting as a
sponge for members of the miR-125 family (Chen
et al., 2017). In the same line, we recently found that
circPVT1 is upregulated in tumor tissues of HNSCC
patients. Patients with high circPVT1 levels have
poorer overall survival in comparison with those
exhibiting low circPVT1 levels (Verduci et al., 2017).
Multivariable analysis confirmed the correlation
between high circPVT1 levels and reduced overall sur-
vival [43]. The onco-circular RNA circPVT1 exerts its
role in HNSCC by acting as a sponge for the miRNA-
497-5p, a tumor suppressor miRNA associated with
p53 mutations in several cancers (Guo et al., 2013;
Huang et al., 2015; Li et al., 2011; Verduci et al.,
2017; Wang et al., 2015). It is clear that even small cir-
cular RNA, such as circPVT1, which has a length of
approximately 400 bp and comes from a single exon
of the long noncoding PVT1 gene, can bind more than
one miRNA and act as a gene expression regulator in
cancer.
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Exosomes are small membrane vesicles released by
most cell types with an approximate size of 40–
100 nm. They are known for their specific cargos of
proteins, mRNAs, and miRNAs, with the potential to
be used as biomarkers for diagnosis of human diseases
(Li et al., 2015c; Pant et al., 2012). Li et al. (2015c)
showed for the first time the presence of circRNAs in
exosomes derived from cancer cells using RNA
sequencing (Li et al., 2015c). Interestingly, circRNAs
in exosomes, named exo-circRNAs, are more abun-
dant in exosomes compared to the cytoplasm of pro-
ducer cells. In addition, exo-circRNAs have been
identified in serum of healthy donors (Li et al., 2015c).
The presence of both circRNAs and miRNAs in exo-
somes suggests the presence of miRNA sponging
mechanisms inside these vesicles.
circRNAs have been found also in human cell-free
saliva (CFS) from healthy donors (Bahn et al., 2015).
By RNA sequencing, Bahn et al. (2015) showed the
presence of miRNAs, Piwi-interacting RNAs, and
circRNAs in CFS. It would be interesting to under-
stand if the presence of these small RNAs in CFS is
related to their interconnected mechanism of action.
Interestingly, ontology analysis of the genes overlap-
ping circRNAs indicates that salivary circRNAs are
putatively involved in intercellular signaling and in
inflammatory responses, opening the possibility of
using saliva, an easily accessible body fluid, for detec-
tion of this new class of biomarkers of human dis-
eases.
6. circRNA therapeutics in cancer: a
glance at the molecular pathways of
circPVT1
A growing number of studies showed that circRNAs
play an important role in cancer. In fact, the same bio-
chemical characteristics that make them suitable
biomarkers may make circRNAs promising thera-
peutic targets. Interestingly, circRNAs can act in
Fig. 3. Cancer biomarkers and gene expression signatures. The noncoding part of the genome plays an important role in the regulation of
gene expression in cancer (Harrow et al., 2012).
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oncogenic molecular pathways involving different
molecules, such as miRNAs, long noncoding RNAs,
RNA-binding proteins, and transcription factors. As
an example, we discuss below our recent work on
circPVT1 (Verduci et al., 2017). We showed that
circPVT1, which comes from an exon of the long non-
coding RNA PVT1, is a master regulator of HNSCC
pathogenesis. Considering the upregulation of circPVT1
in cancer tissues, we assume that the splicing mechanism
that generates circPVT1 from its host gene is preferred
relative to other RNA splicing isoforms transcribed
from the same gene, at least in the context of HNSCC
oncogenesis. circPVT1 acts in HNSCC as a mediator of
the oncogenic activities of mutant p53. Since TP53 is the
most frequently mutated gene in human cancers (Kan-
doth et al., 2013), it is reasonable to theorize that
circPVT1 could have a central role also in other type of
cancer.
We showed that circPVT1 expression is transcrip-
tionally enhanced by the mut-p53/YAP/TEAD com-
plex (Verduci et al., 2017). circPVT1 is also able to
regulate its own expression and to recruit preferen-
tially the mut-p53/YAP/TEAD complex to its pro-
moter region. To the best of our knowledge, it is the
first example of how a circRNA is able to regulate
its own expression level, opening a new perspective
for the study of circRNAs’ mechanism of regulation.
The oncogenic phenotype mediated by circPVT1 is
explicated in HNSCC by its miRNA target, miR-497-
5p. Note that our study did not exclude targeting of
other miRNAs by circPVT1. Considering the tumor
suppressor role of miR-497-5p in several cancers
(Guo et al., 2013; Huang et al., 2015; Li et al., 2011;
Wang et al., 2015), the finding that circPVT1 is able
to sponge miR-497-5p opens a new avenue of
research in other tumor types. The central roles
played by circPVT1 in controlling the oncogenic
phenotype, acting at both the transcriptional and
post-transcriptional levels, put this circRNA in a
privileged position as a therapeutic target. Thus, not
only the exceptional stability and high abundance of
circRNAs make them promising therapeutic targets,
but also their dominant functions in molecular path-
ways offer anticancer effect.
Up to now, different mechanisms of action have
been attributed to different circRNAs. What remains
poorly studied is the possibility that the same cir-
cRNAs can act in the same molecular pathway in dif-
ferent ways. We showed that circPVT1 acts both in
the nucleus, by interacting with transcription factors
and a nuclear cofactor, and in the cytoplasm, by
sponging a specific miRNA. Presumably, additional
circRNAs might employ more than one mode of
action. Revealing the putative combined mechanisms
of a circRNA would be very helpful for detailed char-
acterization of oncogenic molecular pathways.
Although there are not yet any preclinical reports
that use circRNAs as therapeutic targets for cancer
treatment, this scenario is likely to change in the near
future. Regarding circRNAs overexpressed in cancer, a
possible therapeutic approach could be the use of
siRNA against its sequence (Kristensen et al., 2018).
Similarly to the approach adopted in vitro from us and
others (Kristensen et al., 2018; Verduci et al., 2017),
the designed siRNA should target the unique back-
splice junction of oncogenic circRNAs, avoiding any
interference with the linear host gene. In the case of
downregulated circRNAs in cancer, the restoration of
the tumor suppressor circRNA level could be achieved
by cloning the circRNA sequence and its regulatory
flanking regions (Verduci et al., 2017). One of the
main issues with circRNAs as a therapeutic approach
is finding the best way to deliver in vivo the siRNAs or
vectors expressing circRNA. Moreover, studies focus-
ing on deeper characterization of circRNA biogenesis
could be helpful to find a way to regulate their expres-
sion working on factors, such as splicing factors,
responsible for circRNA biogenesis.
7. Concluding remarks
Gene expression is the result of multiple levels of regu-
lation in both normal and pathological conditions.
The noncoding part of the genome, represented by
small and long noncoding RNAs, plays an important
role in the regulation of gene expression in human dis-
eases and especially in cancer. circRNAs and miRNAs
are two of the main characters of this regulation (Aure
et al., 2015; Stahlhut and Slack, 2013) (Fig. 3). cir-
cRNAs were considered in the past the outcome of
transcriptional noise. Nowadays, they have become an
important research subject, attracting interest from dif-
ferent areas, including the field of cancer research. As
we described, circRNAs’ different mechanisms of
action, their high stability, and their presence in acces-
sible body fluids make circRNAs promising biomark-
ers and potential targets for therapeutic interventions,
especially in personalized medicine. The study of the
emerging circRNA–microRNA code will provide a
novel understanding of molecular pathways involving
pathogenesis-related gene expression.
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